Hikma launches generic Vyvanse

Hikma is introducing generic Vyvanse (lisdexamfetamine dimesylate) 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70mg capsules.

“We are pleased to have launched our generic version of Vyvanse today immediately upon receiving FDA approval, providing one of the first generic versions of this important medicine to patients and healthcare providers in the United States,” said Brian Hoffmann, president of generics at Hikma. “This launch is the latest example of our ability to successfully deliver on our pipeline and launch new products, expanding access to needed medicines for our customers and their patients.”

[Read more: Hikma intros Kloxxado]

Hoffman added, “Patients across the United States are currently experiencing shortages of ADHD medicines like lisdexamfetamine. We are eager to work with the U.S. Drug Enforcement Administration to obtain adequate supplies of raw materials that would enable Hikma to expediently use its strong US-based manufacturing and distribution capabilities to help address shortages of this essential medicine.”

Vyvanse had a market value of approximately $5.1 billion in the 12 months ending June 30, 2023, per IQVIA.

[Read more: Hikma to acquire Custopharm]